

Spring 5-10-2016

Demonstrating process performance comparability of the Keytruda[®] upstream process after transfer and scale-up to different manufacturing sites

Jurgen van de Lagermaat
MSD-Oss

Follow this and additional works at: http://dc.engconfintl.org/cellculture_xv



Part of the [Biomedical Engineering and Bioengineering Commons](#)

Recommended Citation

Jurgen van de Lagermaat, "Demonstrating process performance comparability of the Keytruda[®] upstream process after transfer and scale-up to different manufacturing sites" in "Cell Culture Engineering XV", Robert Kiss, Genentech Sarah Harcum, Clemson University Jeff Chalmers, Ohio State University Eds, ECI Symposium Series, (2016). http://dc.engconfintl.org/cellculture_xv/128

This Abstract is brought to you for free and open access by the Proceedings at ECI Digital Archives. It has been accepted for inclusion in Cell Culture Engineering XV by an authorized administrator of ECI Digital Archives. For more information, please contact franco@bepress.com.

Demonstrating Process Performance Comparability of the Keytruda® Upstream Process after Transfer and Scale-Up to Different Manufacturing Sites

Jürgen van de Lagemaat, Global Vaccines & Biologics Commercialization, Process Development & Commercialization Upstream Processing, MSD-Oss, The Netherlands

Keywords: Comparability, Technology Transfer, Scale-Up, Keytruda®, Upstream Process Performance

Abstract:

The Keytruda® drug substance manufacturing process was transferred and scaled up from a donor manufacturing site (12,500 L bioreactor WV) to two additional recipient sites (12,000 L and 22,000 L bioreactor WV) to further expand drug substance production capacity of Merck's novel monoclonal antibody against PD-1. Process facility fit into the recipient manufacturing facilities was required due to differences in equipment and operation as compared to the donor site and therefore upstream process performance comparability needed to be demonstrated (regulatory requirement). A three-level comparability approach was used, whereby upstream intermediate product quality (Level 1), cell culture performance KPAs (Level 2) and cell culture performance profiles (Level 3) data of the two recipient sites were compared with data of the donor reference process. In this case study, the author will present the comparability approach and (statistical) acceptance criteria applied, upstream process performance attributes selected and discuss key comparability results and conclusions.